Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Progress in Medicinal Chemistry
|
February 7, 2013
Advances in the discovery of selective JAK inhibitors
Christel J Menet, Luc Van Rompaey, Raphaël Geney
Journal of Alzheimer'S Disease : JAD
|
April 24, 2010
Peroxisome proliferator-activated receptor gamma enhances the activity of an insulin degrading enzyme-like metalloprotease for amyloid-beta clearance
Ira Espuny-Camacho, Diana Dominguez, Pascal Merchiers, et al.
Cancers
|
October 27, 2019
Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method
Tal Flieswasser, Valérie Camara-Clayette, Alina Danu, et al.
Nature Communications
|
July 10, 2026
Engineering trispecific IL-2 receptor agonistic antibodies through geometry optimization for enhanced Treg targeting
Valentina Lykhopiy, Emilie Pollenus, Laurie Rangan, et al.
Theranostics
|
January 3, 2024
Generic design principles for antibody-based tumour necrosis factor (TNF) receptor 2 (TNFR2) agonists with FcγR-independent agonism
Mohamed A Anany, Stefanie Haack, Isabell Lang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies
Philippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 6, 2013
Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases
Luc Van Rompaey, René Galien, Ellen M van der Aar, et al.
Nature Medicine
|
July 1, 2020
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents
Carsten Riether, Thomas Pabst, Sabine Höpner, et al.
Journal of Medicinal Chemistry
|
November 5, 2014
Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634
Christel J Menet, Stephen R Fletcher, Guy Van Lommen, et al.
Cell Chemical Biology
|
September 30, 2025
Valence and avidity determine the agonistic activity of anti-TNFR2 nanobody fusion proteins
Mohamed A Anany, Daniela Siegmund, Olena Zaitseva, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Progress in Medicinal Chemistry
|
February 7, 2013
Advances in the discovery of selective JAK inhibitors
Christel J Menet, Luc Van Rompaey, Raphaël Geney
Journal of Alzheimer'S Disease : JAD
|
April 24, 2010
Peroxisome proliferator-activated receptor gamma enhances the activity of an insulin degrading enzyme-like metalloprotease for amyloid-beta clearance
Ira Espuny-Camacho, Diana Dominguez, Pascal Merchiers, et al.
Cancers
|
October 27, 2019
Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method
Tal Flieswasser, Valérie Camara-Clayette, Alina Danu, et al.
Nature Communications
|
July 10, 2026
Engineering trispecific IL-2 receptor agonistic antibodies through geometry optimization for enhanced Treg targeting
Valentina Lykhopiy, Emilie Pollenus, Laurie Rangan, et al.
Theranostics
|
January 3, 2024
Generic design principles for antibody-based tumour necrosis factor (TNF) receptor 2 (TNFR2) agonists with FcγR-independent agonism
Mohamed A Anany, Stefanie Haack, Isabell Lang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies
Philippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 6, 2013
Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases
Luc Van Rompaey, René Galien, Ellen M van der Aar, et al.
Nature Medicine
|
July 1, 2020
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents
Carsten Riether, Thomas Pabst, Sabine Höpner, et al.
Journal of Medicinal Chemistry
|
November 5, 2014
Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634
Christel J Menet, Stephen R Fletcher, Guy Van Lommen, et al.
Cell Chemical Biology
|
September 30, 2025
Valence and avidity determine the agonistic activity of anti-TNFR2 nanobody fusion proteins
Mohamed A Anany, Daniela Siegmund, Olena Zaitseva, et al.
Page
of 2